AstraZeneca drug prices evolving in response to Trump policy, executive says

July 27 (Reuters) - AstraZeneca has been adjusting its pricing strategy for new drug launches in response to U.S. President ...
China Daily Global Edition

AstraZeneca announces plans for new innovations for China

Sharon Barr, executive vice-president of biopharmaceuticals R&D at AstraZeneca, delivers a speech at AstraZeneca R&D China ...

AstraZeneca: Q2 2026 Results Were All Right, But Farxiga Poses Risks

AstraZeneca delivered solid core EPS growth of 18% YoY, while revenue growth came in line with expectations for the full year ...

AstraZeneca's drug pipeine is splitting opinion among City analysts

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) drug pipeline is splitting opinion among City brokers, with Citibank upgrading its ...
Fierce Biotech

AstraZeneca execs ‘very confident’ in homegrown ADC pipeline despite scrapping 2 candidates

AstraZeneca executives told Fierce they are “very confident” in the pharma’s in-house pipeline of antibody-drug conjugates ...

A.P. inks pact with AstraZeneca to set up Genomic Solutions Centre in Amaravati

Andhra Pradesh partners with AstraZeneca to launch a Genomic Solutions Centre in Amaravati for advanced cancer detection and treatment.

AstraZeneca's rare disease drug misses main goal in late-stage trial

July 27 (Reuters) - AstraZeneca said on Monday its rare disease drug Ultomiris failed a late-stage trial in patients with a ...

AstraZeneca's trial flop raises a bigger question: Is its pipeline premium becoming more vulnerable?

For years, AstraZeneca has commanded one of the richest valuations among large European pharma companies on the assumption that it consistently delivers results.
GlobalData on MSN

AstraZeneca reports Phase III results for Ultomiris and Sone-Ve

In the ALXN1210-TMA-313 Phase III trial, Ultomiris did not achieve statistical significance for event-free survival.